Fibrogen is reeling from the worst case of data manipulation in years, but six weeks after the scandal broke, the drug maker still hasn’t explained why or how it happened, or identify the people ...

Alzheimer’s disease research has had a tumultuous year. First, patients finally got a new treatment when the FDA approved Biogen’s Aduhelm, setting off a chorus of criticism and challenges for the ...